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Abstract: In Duchenne muscular dystrophy (DMD), the activation of proinflammatory and metabolic
cellular pathways in skeletal muscle cells is an inherent characteristic. Synthetic glucocorticoid
intake counteracts the majority of these mechanisms. However, glucocorticoids induce burdensome
secondary effects, including hypertension, arrhythmias, hyperglycemia, osteoporosis, weight gain,
growth delay, skin thinning, cushingoid appearance, and tissue-specific glucocorticoid resistance.
Hence, lowering the glucocorticoid dosage could be beneficial for DMD patients. A more profound
insight into the major cellular pathways that are stabilized after synthetic glucocorticoid administration
in DMD is needed when searching for the molecules able to achieve similar pathway stabilization.
This review provides a concise overview of the major anti-inflammatory pathways, as well as the
metabolic effects of glucocorticoids in the skeletal muscle affected in DMD. The known drugs able
to stabilize these pathways, and which could potentially be combined with glucocorticoid therapy
as steroid-sparing agents, are described. This could create new opportunities for testing in DMD
animal models and/or clinical trials, possibly leading to smaller glucocorticoids dosage regimens for
DMD patients.
Keywords: glucocorticoid physiology; Duchenne muscular dystrophy; skeletal muscle;
steroid-sparing agents
1. Introduction
Duchenne muscular dystrophy (DMD) is an X-linked recessive skeletal muscle disorder affecting
around one in 3500 boys. It is characterized by muscle weakness and wasting with a clinical onset
at around 4 years of age. The absence of dystrophin, the protein providing a link between the
extracellular matrix and the myocyte cytoskeleton, destabilizes the dystrophin-associated protein
complex (DAPC), a large transmembrane protein complex that acts as a shock absorber during muscle
contraction, a receiver and transducer of cellular signals and as a scaffold for signaling proteins [1,2].
Abnormal shock absorption is thought to result in increased sarcolemmal damage in the myocyte
during exercise. Aberrant signal transduction in DMD is believed to result from the disturbed
link between neuronal nitric oxide synthase (nNOS), dystrophin, and the DAPC. Stretch-activated
channels are located downstream of dystrophin that lead to the activation of the extracellular signal
regulated kinase-mitogen activated protein kinase (ERK-MAPK) cascade, along with increased Ca2+
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influx, in DMD. Together, these pathological mechanisms induce disorganized muscle with myofiber
hypertrophy and necrosis, inflammation, fibrosis, and fat deposition [3–5].
Administration of glucocorticoids (GCs) can counteract these phenomena in patients with DMD.
Different GC dosing regimens can be used. The most commonly used consists of an intake of
0.75 mg/kg/day of prednisone. This is based on the strength and functional outcomes in randomized
controlled trials (RCTs), as summarized in the systematic review of Matthews et al. [6]. Deflazacort is
another commonly used GC. These GCs prolong ambulation and mildly improve muscle strength.
The major effect of GCs is believed to reside in their inhibition of the transcription factor nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-κB), being the master inducer of inflammation.
Unfortunately, GCs can induce several side-effects, such as suppression of the immune system,
potentially leading to life-threatening infections, arrhythmias, hypertension, hyperglycemia and
glucosuria, cataracts, increased food intake and weight gain, delayed growth, osteoporosis and
fractures, abnormal behavior, insomnia, cushingoid appearance, easy bruising, gastro-intestinal
symptoms, and hirsutism [6,7].
GCs regulate reproduction, development, cell differentiation, inflammation, and responses of the
immune system [8]. GCs bind in the cytoplasm to the glucocorticoid receptor (GR), also known as
Nuclear Receptor Subfamily 3 Group C Member 1 (NR3C1). Two isoforms termed GRα and GRβ
have been described. These are the two main transcriptional isoforms [8–10]. While unstimulated,
the GR resides mainly in the cytoplasm and is chaperoned by two heat shock protein 90 (Hsp90)
molecules, Hsp90-binding protein 23 (p23), Hsp70, and immunophilins, all converging to protect the
GR from degradation and prepare it for GC binding at the receptor site. Binding to the GR releases
the Hsps [8–10]. The GR can translocate from the cytoplasm to the nucleus and back, sensing the
intracellular environment along its journey and interacting with several proteins, thereby creating the
GR interactome. After the binding of GCs to the GR, the actions of the transcription factor can be
divided in genomic and non-genomic functions [8–11]. One of the major targets of the GR is NF-κB, the
major activator of the genes coding for immunoreceptors, proinflammatory cytokines, and chemokines
along with the other important cellular players inhibited by GCs. Genomic effects appear after GC–GR
translocation to the nucleus and subsequent DNA binding, and can result in expression changes in up
to 10–20% of genes [10]. Non-genomic actions occur within minutes and consist of the activation of
Toll-like receptors (TLRs), p38 mitogen-activated protein kinases (MAPKs), c-Jun N-terminal kinases
(JNKs), the NF-κB and activator protein 1 (AP-1), the Janus kinase/signal transducer and activator of
transcription proteins (JAK/STAT), and transforming growth factor-β (TGF-β).
In this review, the current evidence on the cellular pathways that are activated in and interact with
GCs in the DMD myocyte, is summarized and discussed. The impact of glucocorticoid administration is
visualized, thereby showing the normalization or exacerbation of the triggered pathways. Importantly,
the purpose of this review is to discuss putative approaches to downscale the GC dosage in DMD
patients via supplementation of the pathway stabilizing agents. All ongoing clinical trials for
DMD in the USA can be monitored here: https://www.clinicaltrials.gov and in Europe on this site:
https://www.clinicaltrialsregister.eu/.
2. Activation of the Cellular Pathways in Skeletal Muscle Cells in Duchenne Muscular
Dystrophy, the Effects of GC Administration, and Putative Stabilizing Molecules
2.1. The TLR Signaling Pathway in DMD
2.1.1. Genomic and Non-Genomic Effects of TLR Activation
In DMD skeletal muscle, unstable myocyte cell membranes induce TLR activation (TLR4 and
TLR7), resulting in NF-κB activation through the myeloid differentiation primary response 88 (MyD88)
(Figure 1) [9–12]. Furthermore, TLRs recognize the damage-associated molecular pattern (DAMP)
molecules that arise from the destruction of DMD muscle fibers, such as nucleic acids, reactive oxygen
species (ROS), Hsp, and very potent activators of inflammation, such as single stranded RNA (often
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called the ‘danger model’ of the immune system). Upon translocation of NF-κB to the nucleus, NF-κB
activates the expression of proinflammatory genes coding for growth factors, cytokines, chemokines,
cell adhesion molecules, and immunoreceptors [9,13].
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Figure 1. Genomic and non-genomic effects of glucocorticoid receptor (GR) binding to the different 
players of the inflammatory and metabolic pathways involved in the Duchenne muscular dystrophy 
(DMD) myocyte. The pathways indicated in orange are activated, the green indicates a return to the 
physiological status. The GR is depicted in red. Abbreviations: Daxx = death-associated protein, 
FOXO = forkhead box O, GLUT4 = glucose transporter 4, GR = glucocorticoid receptor, IƘB = inhibitor 
of NF-ƘB, IRFs = interferon regulatory factors, Hsp72 = heat shock protein 72, IRS1 = insulin receptor 
substrate 1, JAK/STAT = Janus kinase/signal transducer and activator of transcription proteins, JNK = 
c-Jun N-terminal kinase, NFATc1 = nuclear translocation of nuclear factor of activated T cells c1, NF-
ƘB = nuclear factor kappa-light-chain-enhancer of activated B cells, P = phosphorylation, p38 = p38 
mitogen-activated protein kinases, PI3K/Akt/mTOR = Phosphoinositide 3-kinases/protein kinase 
B/mammalian target of rapamycin pathway, RAF/RAS/ERK = Rapidly Accelerated 
Fibrosarcoma/Ras-extracellular signal-regulated kinase, S6K1 = ribosomal protein S6 kinase beta-1, 
SMAD3 and -6 = Mothers Against Decapentaplegic homolog 3 and 6, TGF-β = transforming growth 
factor-β, TLR= Toll-like receptors. 
A second, third, and fourth branch of the activated TLR pathway consists of interferon 
regulatory factors (IRFs), p38, and JNK activation. JNK is an important signaling component 
belonging to the group of MAPK (to which p38 also belongs). It controls proliferation and apoptosis 
among other functions. MAPK activation results in tumor necrosis factor (TNF) production and the 
production of interleukins, such as IL-1 and IL-6 [9,14,15]. Besides, JNK phosphorylates the nuclear 
factor of activated T cell c1 (NFATc1), a transcription factor able to activate genes coding for utrophin. 
NFATc1 phosphorylation results in its nuclear export [16]. 
Membrane instability and the ensuing TLR, NF-ƘB, MAPK, and IRF activation in DMD are 
among the major sources driving chronic inflammation, which is characteristic of the disease. As 
depicted in Figure 1, the major drugs able to stabilize these activated pathways are GCs by binding 
to NF-ƘB and MAPKs and through nuclear translocation of NFATc1. 
  
Figure 1. Genomic and non-genomic effects of glucocorticoid receptor (GR) binding to the different
players of the inflammatory and metabolic pathways involved in the Duchenne muscular dystrophy
(DMD) myocyte. The pathways indicated in orange are activated, the green indicates a return
to the physiological status. The GR is depicted in red. Abbreviations: Daxx = death-associated
protein, FOXO = forkhead box O, GLUT4 = glucose transporter 4, GR = glucocorticoid receptor,
IκB = inhibitor of NF-κB, IRFs = interferon regulatory factors, Hsp72 = heat shock protein 72,
IRS1 = insulin receptor substrate 1, JAK/STAT = Janus kinase/signal transducer and activator of
transcription proteins, JNK = c-Jun N-terminal kinase, NFATc1 = nuclear translocation of nuclear
factor of activated T cells c1, NF-κB = nuclear factor kappa-light-chain-enhancer of activated B cells,
P = phosphorylation, p38 = p38 mitogen-activated protein kinases, PI3K/Akt/mTOR = Phosphoinositide
3-kinases/protein kinase B/mammalian target of rapamycin pathway, RAF/RAS/ERK = Rapidly
Accelerated Fibrosarcoma/Ras-extracellular signal-regulated kinase, S6K1 = ribosomal protein S6 kinase
beta-1, SMAD3 and -6 = Mothers Against Decapentaplegic homolog 3 and 6, TGF-β = transforming
growth factor-β, TLR= Toll-like receptors.
A second, third, and fourth branch of the activated TLR pathway consists of interferon regulatory
factors (IRFs), p38, and JNK activation. JNK is an important signaling component belonging to the
group of MAPK (to which p38 also belongs). It controls proliferation and apoptosis among other
functions. MAPK activation results in tumor necrosis factor (TNF) production and the production
of interleukins, such as IL-1 and IL-6 [9,14,15]. Besides, JNK phosphorylates the nuclear factor of
activated T cell c1 (NFATc1), a transcription factor able to activate genes coding for utrophin. NFATc1
phosphorylation results in its nuclear export [16].
Membrane instability and the ensuing TLR, NF-κB, MAPK, and IRF activation in DMD are among
the major sources driving chronic inflammation, which is characteristic of the disease. As depicted in
Figure 1, the major drugs able to stabilize these activated pathways are GCs by binding to NF-κB and
MAPKs and through nuclear translocation of NFATc1.
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2.1.2. TLR Pathway Stabilizers
Lowering GC dosage regimens for DMD patients could be achieved by stabilizing parts of
the activated TLR pathways. Two major modes of action could be targeted: (1) preventing the
DAMPs released via myofiber destruction from binding to the TLR receptor and (2) blocking signal
transduction through the activated pathways. Scanning for molecules with such properties yielded
antibodies, microRNA (miRNA) inhibitors, free radical scavengers, p38 and/or JNK inhibitors, and
NF-κB inhibitory peptides [15,17]. Starting with the antibodies, NI-0101 (Novimmune, Plan-les-Ouates,
Switzerland) is the first anti-TLR4 antibody designed for rheumatoid arthritis (RA). With no adverse
effects among healthy volunteers [16], and given that some pathways are shared between DMD and
RA in pathophysiology [17,18], this antibody may be worth considering for DMD treatment. miRNAs
are non-coding RNAs that can fine-tune gene expression during post-transcriptional regulation [15].
Nine miRNAs were reported to be increased in mdx mice, the murine model for DMD, and all are
suppressed by prednisone and vamorolone (VBP15): miR-142-5p, miR-142-3p, miR-146a, miR-301a,
miR-324-3p, miR455-5p, miR-455-3p, miR-497, and miR-652. Their presence in DMD skeletal muscles,
their interaction with cellular pathways and if known, their specific target protein(s) are listed in
Table 1. The vast majority has not been explored yet in DMD. Both miR-21 and miR-146a are specific
for TLR4, and are increased in DMD skeletal muscle. miRNA-142-3p is increased in inflammatory
cells and is suspected to be increased in invading inflammatory cells in DMD muscles. It interacts
with glycoprotein 130 (gp130), a component of interleukin-6 receptor [15,19–24]. The muscle-enriched
miRNA-206, which belongs to the so-called myomiRNAs, is increased in the serum and muscle of DMD
patients [23]. It activates components involved in skeletal muscle growth and differentiation such as
histone deacetylase 4 (HDAC4), polypirimidine tract-binding protein (PTB), utrophin, follistatin-like
1 (Fstl1), connexin 43 (Cx43), and the tissue inhibitor of metalloproteinases 3 (TIMP3). It inhibits
insulin-like growth factor-1 (IGF-1) and paired box 3 and 7 (Pax3 and -7) [25]. The downregulation of
miRNA-206 increased motor functions in mdx mice and provided a milder disease phenotype [26]. The
inhibition of miR-21 and miR-146a could further counteract the effects of TLR4 activation in DMD.
Table 1. Overview of miRNAs in Duchenne muscular dystrophy (DMD), their influence on other
cellular pathways and their target protein.
Molecule Presence in DMD Involved Pathway + Target Protein(s)
miR-21 Increased in skeletal muscle TLR4 [16]
miR-142-5p Unknown -
miR-142-3p
Increased in inflammatory cells,
probably also during skeletal
muscle invasion [22]
gp130 [24]
miR-146a Increased in skeletal muscle [23] TLR4 [16]
miR-206 Increased in skeletal muscle [23]
Activation of HDAC4, PTB, Utrophin,
Fstl1, Cx43, TIMP3. Inhibition of IGF-1,







Another approach could involve targeting p38 MAPK and/or JNK. The treatment of mdx mice
with alpha lipoic acid (ALA)/L-carnitine (L-Car), a free radical scavenger able to modulate p38 and
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JNK, resulted in decreased NF-κB activity in the mdx diaphragm, as listed in Table 2. It decreased
the plasmatic creatine kinase level, the matrix metalloproteinase activity, NF-κB activity, antioxidant
enzyme activity, and lipid peroxidation in mdx diaphragm [27,28]. Carnitine metabolism has been
described to be perturbed in DMD. More specifically, both palmitoyl carnitine transferase and palmitoyl
coenzyme A hydrolase are increased, whereas palmitoyl carnitine hydrolase is absent in DMD. The
latter is an important component in carnitine metabolism and could explain the results obtained
in a pilot study conducted in 2013 on a small number of steroid-naïve DMD boys with L-carnitine
supplementation, showing no difference in the function of the upper and lower extremities [29,30].
An inhibitor of p38 named SB203580 provided contradictory results in mdx myotubes during in vitro
experiments and in mdx mice tissue and seems to be of lesser value as a therapeutic molecule. Indeed,
it prolonged survival of mdx myotubes in vitro under oxidative stress conditions. In mdx mice, the p38
MAPK phosphorylation levels were normal [27,31]. Another study on mdx mice with the JNK1
inhibitory protein (JIP1) showed attenuation of muscle fiber necrosis [32]. Deflazacort, an oxazoline
derivative of prednisone, enhances the transcription of the utrophin gene, thereby compensating in
part for the loss of dystrophin by upregulating the activity of calcineurin phosphatase through JNK1.
This leads to the nuclear translocation of NFATc1, a stimulator of the utrophin gene [16]. JIP1 seems
promising because it increases mdx myotube viability in vitro and decreases mdx myofiber destruction
in vivo. However, further studies are needed [33]. The direct inhibition of IRF in DMD has not been
described to date; all reported IRF inhibitions were indirect [34,35].
Table 2. Overview of p38 mitogen-activated protein kinases (p38 MAPK) and c-Jun N-terminal kinase
(JNK) stabilizing molecules: results in mdx myotubes (in vitro) or mice (in vivo), finished clinical trials
and results, ongoing clinical trials and due dates, and putative molecules.
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An important effector of the TLR pathway is the proinflammatory transcription factor NF-κB
(60 kDa), which is activated in DMD [36]. Many molecules have been tested to target this master
regulator of inflammation (Table 3). In mdx myotubes or mice, several studies were performed with
NF-κB inhibitors, such as NK-κB Essential MOdulator (NEMO)-Binding Domain (NBD), the antioxidant
pyrrolidine dithiocarbamate (PDTC), the inhibitor of lipid peroxidation IRFI-042, and the free radical
scavengers, N-acetylcysteine (NAC) and (ALA)/L-carnitine (L-Car) [31,37–42]. Unfortunately, NBD
induced renal toxicity in mdx mice despite encouraging results showing decreased necrosis and
increased regeneration in the diaphragm and hind limb muscles [37,43,44]. Administration of the
NF-κB inhibitor PDTC showed increased strength and muscle regeneration along with decreased
fatigue and muscle necrosis in mdx mice. In the diaphragms of mdx mice, PDTC influenced the
diameter and density of myofibers [45,46]. Several other NF-κB inhibitors can also be considered.
IRFI-042 showed a decrease in necrosis and an increase in regeneration in mdx muscle [46]. While
NAC decreased the membrane permeability and increased the stretch-induced force in mdx muscle,
as well as decreased myofiber necrosis in an mdx diaphragm, it caused severe side-effects, such as
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a marked drop in body and liver weight [47–52]. Edasanolexent (CAT-1004, Catabasis, Cambridge,
MA, USA) an NF-κB inhibitor, improved resistance to eccentric contraction-induced damage in mdx
muscle [53]. The Phase I/II trial (Move DMD®, NCT02439216) reported minor side-effects, such
as mild gastrointestinal symptoms and headache. Inhibition of NF-κB was noticed. The results
from the Phase II clinical trial are pending, whilst Phase III (PolarisDMD, NCT03703882) and Phase
III open label studies (GalaxyDMD, NCT03917719) are currently ongoing [54–56]. AP-1 is always
mentioned in the same breath with NF-κB in GC administration. It is an activator of utrophin [57].
Batimastat (BB-94) inhibited AP-1 in mdx muscle [58]. AP-1 has been poorly studied in DMD. One
study reported its upregulation in mdx muscle tissue [59], one pinpointed its importance in skeletal
muscle regeneration [60], and one linked it to oxidative stress in skeletal muscle cells [61]. Inhibition
of AP-1 by batimastat would imply absence of utrophin activation and seems less interesting as a
therapeutic option in DMD.
Table 3. Overview of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and
activator protein 1 (AP-1) stabilizing molecules: results in mdx myotubes (in vitro) or mice (in vivo),
finished clinical trials and results, ongoing clinical trials and due dates, and putative molecules.
Molecule Involved Pathway Results in mdx Myotubes orMice
Finished Clinical Trials +
Results
Ongoing Clinical
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Batimastat (BB-94) AP-1 inhibition
Reduction of proinflammatory
AP-1 expression in mdx
muscle [56]
- -
2.2. The JAK/STAT Signaling Pathway in DMD
2.2.1. Genomic and Non-Genomic Effects of JAK/STAT Activation
The JAK/STAT pathway is involved in skeletal muscle physiology and pathology. Skeletal muscles
are producers of IL-6, thereby earning the title of myokine, which has warning potential towards
other organs, such as the pancreas and liver, resulting in glucose tolerance and production while
harboring anti-inflammatory properties. The binding of cytokine IL-6 to its receptor (IL-6R) and
to the protein gp130 homodimer results in the activation of JAK and STAT3, which subsequently
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translocates to the nucleus. In DMD, IL-6 production is increased and plays a proinflammatory role,
leading to the exhaustion of satellite cells [62,63]. In mdx mice, STAT3 and IL-6 are upregulated.
Moreover, the chronic IL-6 elevation produced by T cells and macrophages, as part of the chronic
inflammation seen in DMD, plays an important role in the muscle pathology leading to the activated
JAK/STAT pathway and NF-κB [64]. However, the expression patterns of STAT3 and IL-6 are
different in individual mdx muscles, leading to aggravation of the phenotype in one muscle, while
amelioration is observed in another muscle [65,66]. GCs and IL-6 synergistically activate the IL-6
response element through GR and STAT3 [63,67]. The JAK/STAT pathway directly communicates
through STAT3 and the suppressor of cytokine signaling 3 (SOCS3) with the Rapidly Accelerated
Fibrosarcoma/Ras-extracellular signal-regulated kinase (RAF/RAS/ERK) and the Phosphoinositide
3-kinases/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) pathways [64,65]
(Figure 1). These pathways are cell controlling towers for cell survival, motility, and proliferation after
extracellular signaling. In mdx mice, these pathways are activated to increase the expression of α7
integrin and compensate for the loss of dystrophin [66].
2.2.2. JAK/STAT Pathway Stabilizers
As mentioned above, the versatile function of JAK/STAT in cell signaling makes it a difficult target
in pathway stabilization. The controversial results observed in mdx mice after using an antibody directed
against IL-6 (tocilizumab, RoActemra®, Roche, Basel, Switzerland) requires careful consideration
before it can be part of the list of putative molecules for DMD treatment (Table 4). For mdx mice,
one study reported a decrease in mdx muscle inflammation, while another study described an increase
in inflammation [64,66,68,69]. Valproic acid (VPA) has been described to inhibit apoptosis by activating
the PI3K/Akt/mTOR pathways in mdx mice. It ameliorated the mdx phenotype by increasing the
sarcolemmal integrity, and decreasing fibrosis and hind limb contractures in mdx muscle and mice [70].
It may be worth considering VPA supplementation for DMD patients on a GC regimen.
Table 4. Overview of Janus kinase/signal transducer and activator of transcription proteins (JAK/STAT)
and mammalian target of rapamycin pathway (mTOR) stabilizing molecules: results in mdx myotubes
(in vitro) or mice (in vivo), finished clinical trials and results, ongoing clinical trials and due dates, and
putative molecules.




Trials + Due Dates
Tocilizumab
(RoActemra®) IL-6R antagonist
Decrease and increase in mdx
muscle inflammation [64,66] - -
valproic acid (VPA) PI3K/Akt/mTORpathways activator
Increase in sarcolemmal
integrity and decrease in
fibrosis in mdx muscle [70]
- -
2.3. The TGF-β Signaling Pathway in DMD
2.3.1. Genomic and Non-Genomic Effects of TGF-β Activation
After activation, TGF-β phosphorylates the Mothers Against Decapentaplegic homolog 3 and 6
(SMAD3 and -6) and interacts with the death-associated protein Daxx. Two phosphorylated SMAD3s
bind to an SMAD4. This complex subsequently translocates to the nucleus. After translocation to
the nucleus, the GR will prevent binding SMAD3, 4, 6, and Daxx to the DNA [9]. SMAD plays an
important role in muscle cell growth and differentiation [71]. The T- and B cells present in DMD
muscle, along with the DMD myotubes themselves, secrete TGF-β. At high doses, TGF-β can induce
fibrosis in skeletal muscle by stimulating fibroblasts and enhancing a switch to the myofibroblast
phenotype, thereby prompting the deposition of the extracellular matrix (ECM), pitchforking it to the
‘master regulator of fibrosis’. In contrast, low doses of TGF-β stimulate the proliferation of myoblasts
to develop them into fast-type muscle fibers. Indeed, the suppression of TGF-β1 during skeletal
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muscle regeneration induces the appearance of slow-type MHC, thus guiding regeneration towards the
slow muscle fiber type phenotype. Myostatin is intrinsically linked to TGF-β [72]. TGF-β/myostatin
activation has been widely studied in DMD [71–76]. GCs bind to SMAD and Daxx, and can interfere
with satellite cell differentiation, which is detrimental to DMD patients. Chronic GC use has been
shown to reduce fibrosis in DMD muscle [77].
2.3.2. TGF-β/Myostatin Pathway Stabilizers
TGF-β and myostatin inhibitors comprise the majority of molecules currently being/have been
tested in DMD clinical trials (Table 5) [78]. Two TGF-β inhibitors are losartan and suramin. Losartan
(Cozaar®, MSD, Kenilworth, NJ, USA) is an angiotensin II type 1 receptor blocker used in the treatment
of high blood pressure. It reduces the expression of TGF-β and the production of connective tissue
growth factor (CTGF) [79]. When used in mdx mice, losartan inhibited fibrosis in the mdx muscle and
decreased fibrosis and increased muscle fiber density in the mdx diaphragm, while another study
on mdx mice did not show any difference in skeletal muscle [78,80,81]. Suramin (Germanin®, Bayer,
Leverkusen, Germany), is an anti-parasitic and anti-neoplastic FDA approved molecule, used to treat
African sleeping sickness and river blindness or treat some sorts of cancer. It interacts with TGF-β by
preventing binding to the TGF-β receptor [82]. Suramin was shown to reduce fibrosis and myofiber
necrosis in mdx mice [83]. The proteoglycan decorin has the ability to trap both TGF-β and myostatin,
with interesting results showing fibrosis downscaling (collagen type I levels in the diaphragm) and the
enhancement of muscle regeneration in mdx mice [71,73,74]. Another strategy consists of targeting
activin, one of the members of the TGF-β superfamily, which binds to the activin receptors IIA and IIB
(ACVR2A, ACVR2B). The soluble activin receptor ACE-031 (Acceleron Pharma, Cambridge, MA, USA)
ActRIIB-IgG was tested, due to increased forward pulling tension in mdx mice [84], in a Phase II trial
on DMD patients (2011). The patients showed tolerance towards the molecule with only minor side
effects. However, these side effects resulted in the termination of the study by the USA FDA, despite an
increase in muscle mass [85]. Acvr2b downregulation by the AAV-virus delivery of shRNAs induced
mdx muscle hyperplasia [86]. The bone morphogenic proteins (BMP) are a group of growth factors
which enhance muscle growth and play a role in muscle disorders [87]. Therefore, the following BMP
antagonists could be considered: dorsomorphin, LDN-193189, and Noggin. However, dorsomorphin
is toxic to in vitro grown primary myoblasts [88]. Noggin alleviated the dystrophic phenotype in
mdx mice [88]. Tamoxifen (Hadassah Medical Organization, Ein Kerem, West Jerusalem), a selective
estrogenreceptor modulator, stabilized myofiber membranes, normalized the whole body force, and
reduced fibrosis in the diaphragm in mdx mice [89–91]. A Phase I clinical trial (NCT02835079) is
currently ongoing in Israel, with completion expected in November 2020. A Phase clinical trial III
(TAMDMD, NCT03354039, EudraCT Number: 2017-004554-42) is ongoing in Europe and should
be completed in June 2020. Patients receive in both trials also GCs [92]. The antiparasitic molecule
halofuginone (HT-100) inhibited mdx muscle and diaphragm fibrosis [93,94]. All Phase I/II/III clinical
trials in the USA (HALO-DMD-01, NCT01847573; HALO-DMD-02, NCT01978366; HALO-DMD-03,
NCT02525302) were abrogated after the death of a patient on a high dose of HT-100. Halofuginone
and GCs tend to work in a synergistic manner. Safer molecules derived from halofuginone such as
deoxyhalofuginone have been tested in mdx mice, with positive effects on muscle fiber diameter [95].
Myostatin targeting antibodies include domagrozumab (PF-06252616, Pfizer, New York, NY, USA),
talditercept alpha (anti-myostatin adnectin, RG 6206, BMS-986089, Bristol-Myers Squibb, New York,
NY, USA), and stamulumab (MYO-029, Wyeth Pharmaceuticals, Madison, NJ, USA). A clinical trial
with stamulumab over six months in Becker muscular dystrophy (BMD) patients (completed in January
2007) showed good safety but no increase in skeletal muscle strength [96]. Domagrozumab increased
functional muscle mass and increased body and muscle weight and grip strength. The size of the
tibialis anterior fibers was significantly increased in mdx mice [97]. All clinical trials (NCT02310763 and
NCT02907619) were abrogated in 2018 due to a lack of effectiveness [71,76,78,98]. Currently, talditercept
alpha is being tested in an ongoing Phase I/II trial in the USA (NCT02515669, THUNDERJET), which
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should be completed in May 2020, and a worldwide Phase II/III trial (NCT03039686, SPITFIRE) due in
December 2024. It is worth mentioning that myostatin seems to be associated with the GCs induced
catabolic effect on muscle proteins and less with the suppression of protein synthesis [99]. The
myostatin inhibitory protein follistatin (rAAV1.CMV. huFollistatin344, Nationwide Children’s Hospital,
Columbus, OH, USA) showed an increase in muscle mass, myofiber size, grip strength, and tetanic
force, as well as a decrease in necrosis, fibrosis, and inflammation, in mdx mice [100–103]. Follistatin
was tested in a Phase I/II clinical trial (NCT02354781) completed in 2017, with good results. The TGF-β
pathway can also be modulated by the knockdown of the TGF-β Type I receptor TGFBR1, also known
as activin A receptor type II-like kinase 5 (ALK5), via the exon skipping of ALK5 by specific antisense
oligonucleotides (AONs) [104]. TGF-β activation in DMD induces the upregulation of CTGF [105].
With GCs inducing CTGF, a molecule was developed that can downregulate CTGF: Pamrevlumab
(FG-3019, Fibrogen, San Francisco, CA, USA). This molecule increased muscle strength and endurance
and induced a decrease in apoptosis and fibrosis in mdx muscle [106]. Currently, a Phase II clinical trial
(NCT02606136) is ongoing in the USA, with completion expected in April 2021.
Table 5. Overview of tumor growth factor β (TGF-β) or myostatin stabilizing molecules: results in mdx
myotubes (in vitro) or mice (in vivo), finished clinical trials and results, ongoing clinical trials and due
dates, and putative molecules.
Molecule Involved Pathway Results in mdx Myotubesor Mice
Finished Clinical Trials +
Results
Ongoing Clinical Trials +
Due Dates
Losartan (Cozaar®) TGF-β inhibition
Reduction in fibrosis in mdx
muscle, increased muscle fiber
density, and decreased fibrosis in




Reduction in fibrosis and myofiber
necrosis in mdx mice [83] - -
Decorin TGF-β inhibition
Fibrosis downscaling in the
diaphragm and enhancement of
muscle regeneration in mdx mice
[71,73,74]
- -
ACE-031 TGF-β inhibition Increased forward pulling tensionin mdx mice [84]
Phase II trials (NCT01099761
and NCT01239758) were
completed in 2011 with good
tolerance and increase in
muscle mass. Abrogated due












Dorsomorphin is toxic in in vitro
grown primary myoblasts.
Noggin alleviates the dystrophic





whole body force and reduction of











expected for June 2020.









abrogated in 2016. Phase II
trial (HALO-DMD-02,
NCT01978366) in the USA,
abrogated in 2016. Phase III
trial (HALO-DMD-03,
NCT02525302) in the USA,
abrogated in 2016. Patients
also received GCs.
-
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Table 5. Cont.
Molecule Involved Pathway Results in mdx Myotubesor Mice
Finished Clinical Trials +
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Increase in functional muscle mass
and normal neuromuscular
coordination in mdx mice [97]
Phase II trial (NCT02310763) +
open-label extension study
(NCT02907619) in the USA











Phase I trial completed in 2017
in healthy volunteers with
good tolerance
Phase I/II trial (NCT02515669,
THUNDERJET) ongoing in
the USA. Completion




expected in December 2024.
Patients also received GCs.
Follistatin Myostatininhibition
Increase in muscle mass, myofiber
size, grip strength and tetanic
force, decrease in necrosis, fibrosis,
and inflammation [100–102]
Phase I/II trial (NCT02354781)
with rAAV1.CMV.hu-
Follistatin344 conducted in
the USA was completed in






Increase in muscle strength and
endurance, decrease in apoptosis
and fibrosis in mdx muscle [105]
-
Phase II (NCT02606136)
ongoing in the USA.
Completion expected in April
2021. Patients also received
GCs.
2.4. The Metabolic Pathways in DMD
2.4.1. Genomic and Non-Genomic Effects of Metabolic Pathway Activation
Insulin regulates glucose uptake in the skeletal muscle. DMD muscle presents disturbed insulin
signaling resulting in insulin resistance (IR), possibly due to an abnormal cellular localization of glucose
transporter 4 (GLUT4) (Figure 1). Decrease in molecular chaperone protein Hsp72 plays a role in IR
in skeletal muscle. Besides, it also inhibits JNK and NF-κB. In DMD, the exact status of Hsp72 is not
clear cut and IR occurs independently of GC intake [106–109]. However, when taken for a longer
period of time, GCs will further induce IR. GCs can also induce myopathy through oxidative stress
and the production of factors to counteract this stress. When examining the glucocorticoid sensitivity
in muscle, fast-twitch myofibers have a larger GR density than slow-twitch myofibers, making them
more susceptible to GC toxicity [110,111]. The brain is the largest consumer of glucose and needs
to be fueled in a permanent manner, especially in times of stress. Therefore, the major role of GCs
in skeletal muscle metabolism is blood glucose homeostasis by reducing both glucose uptake and
consumption by the muscles. Further, GCs support catecholamine-induced glycogenolysis and inhibit
the insulin-stimulated synthesis of glycogen in the muscle. GCs also promote the degradation of
protein in the muscle, thereby facilitating gluconeogenesis by providing gluconeogenic amino acids in
the muscle during the synthesis of its own glucose. This keeps glucose in the blood to fuel the brain
during stress. Insulin, on the contrary, exerts opposing effects that enhance glucose utilization by the
muscle [109,111]. In myotubes, GCs reduce insulin-stimulated glucose uptake by diminishing the
translocation of GLUT4 to the cell membrane. This also results in decreased glycogen synthesis. GCs
also block the insulin-receptor-Akt-mTOR-S6K pathway and the insulin-receptor-Akt-FOXO pathway,
culminating in an increase of protein degradation and a decrease of protein synthesis. After insulin
binding to the insulin receptor, GCs block the downstream pathway at the levels of insulin receptor
substrate 1 (IRS1), phosphoinositide 3-kinase (PI3K), protein kinase B (PKB/Akt), mammalian target
of rapamycin (mTOR), ribosomal protein S6 kinase beta-1 (S6K1), and forkhead box O (FOXO). GCs
block amino acid uptake in muscles. All these modulations by GCs converge into hyperglycemia in
the blood, fueling the brain with glucose during stressful events (Figure 1) [109–112].
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2.4.2. Glucose Metabolism Stabilizers
Glucose intolerance and significant changes in blood glucose have been described in DMD
patients [113,114], and glucose metabolism has also been described as a disease marker in the Golden
Retriever Model of DMD [115]. With chronic GC intake inducing IR, it may be worth considering the
use of insulin sensitizers in DMD patients (Table 6). Insulin sensitizers address IR by increasing the
sensitivity of the organs to insulin. The biguanide metformin (Glucophage®, Fortamet®, Riomet®)
induces glucose uptake in skeletal muscle, is widely used in children and teenagers with diabetes type 2,
is safe to use in patients with heart failure, and does not induce weight gain [116]. Metformin was tested
in mdx mice and showed reduced fibrosis in the mdx muscle but no effect on glucose metabolism [117].
It increased twitch and tetanic tension in mdx diaphragm. In vitro, metformin protected the myotubes
from cardiotoxin induced degeneration [118,119]. A Phase I clinical trial (NCT02516085) completed in
2012 in Switzerland showed slowing of the disease process in DMD patients but no change in motor
function [120,121]. Adiponectin is decreased in mdx mice and DMD patients [122,123] and is widely
recognized as an insulin sensitizer. Studies on AdipoRon (adiponectin) in mdx mice revealed a delay
in the disease progression, reduced inflammation, an increase in anti-inflammatory cytokine IL-10,
protection from T-lymphocyte and M1 macrophage infiltration, a transition to the M2 macrophage type,
and a boost of the myogenic program. Similar observations were made in DMD human myotubes
treated with AdipoRon [123–126]. The pharmacological co-inducer of Hsp72, BGP-15, showed
promising results in mdx mice by increasing muscle strength, architecture, and contractile function
in the diaphragm when given at an early age [109,127]. Idebenone was created for the treatment of
Alzheimer’s disease and could be considered an insulin sensitizer [128]. In mdx mice, idebenone
improved running performance [129]. Two Phase II clinical trials (NCT00654784 and NCT00758225,
Delphi extension) were completed in 2007 and 2011 in Belgium; a worldwide Phase III clinical trial
(NCT01027884) was also finished in 2014. These trials showed improved respiratory function in DMD
patients [130–132]. Two phase III clinical trials are ongoing: NCT02814019, SIDEROS expected in
August 2021, and NCT03603288, SIDEROS-E expected in January 2024.
Table 6. Overview of glucose metabolism stabilizing molecules: results in mdx myotubes (in vitro)
or mice (in vivo), finished clinical trials and results, ongoing clinical trials and due dates, and
putative molecules.
Molecule Involved Pathway Results in mdx Myotubes orMice
Finished Clinical Trials +
Results
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macrophage infiltration, switch
to the M2 macrophage type, and
boost of the myogenic program;









function in the mdx diaphragm
when given at early
age [109,127]
- -
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expected for January 2024.
2.5. The Histone Deacetylases HDAC in DMD
2.5.1. Genomic and Non-Genomic Effects of HDAC Activation in DMD
As depicted in Figure 2, several steps of preparation are necessary for GCs to bind to GRs in the
cytoplasm. HDAC6 needs to bind to Hsp90. The deacetylation of Hsp90 provides stable binding to
the GR, followed by the release of the Hsp70-Hsp90 organizing protein (Hop), Hsp40, and Hsp70,
and the stabilization of Hsp90 by cochaperone p23 and immunophilin FK506-binding protein 51
(FKBP51), a potent inhibitor of GR [133]. Therefore, p23 and FKBP51 are both necessary to form a stable
chaperone- and cochaperone heterocomplex with GR. After GCs binding to the GR heterocomplex,
it is believed that, FKBP51 is replaced by FKBP52, subsequently potentiating GR [134,135]. After
translocation to the nucleus, GR binds to the glucocorticoid response elements (GREs) in the DNA
and activates anti-inflammatory genes [9]. The absence of HDAC6 blocks the transfer of the GR to the
nucleus via the creation of an unstable Hsp/GR complex. Further, HDAC2 helps deacetylate GRs in
the nucleus, resulting in a decrease in the transcription of inflammatory genes after NF-κB binds to
the DNA. During the interaction of SMAD6 with the GR, HDAC3 is recruited, leading to decreased
transcription of GR genes [9]. In mdx mice, HDACs are upregulated [136].
2.5.2. HDAC Inhibitors
HDAC inhibitors (HDACis) upregulate follistatin in dystrophic muscle, thereby improving
regeneration. Indeed, HDACis achieve this by inhibiting the activity of Myogenin D (MyoD) [137].
The orphan drug Givinostat (S2170, formerly known as ITF2357) (Table 7) is an HDAC inhibitor that
increases the cross-sectional myofiber area, membrane stability, and endurance, and decreases fibrosis
and inflammation in mdx muscle [138–140]. A Phase I/II trial (NCT01761292) in DMD patients between
8 and 10 years of age (as HDACi only has an impact early in the disease) was completed in 2017 in Italy,
showing good tolerance and a decrease in necrosis, fibrosis, and fatty tissue [141]. Notably, biopsies are
needed to evaluate the progression of the disease under an HDACi regimen, which involves subjecting
patients to an invasive procedure [142]. In Europe and the USA, Phase II/III (NCT03373968) and
III (NCT02851797) trials are ongoing, with completion expected in December 2023 and March 2022,
respectively. HDACis can cause side-effects such as arrhythmias, nausea, vomiting, anorexia, fatigue,
anemia, and liver toxicity [143]. When HDACis are combined with VPA, status epilepticus has been
described [143]. Therefore, HDACis should be handled very cautiously in DMD.
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2.6. The Activation of Nuclear Receptors in DMD
Mitochondria are involved in the pathogenesi of DMD, by xhibi ing lower expression of
mitochondrial ge es along with disturbed oxidative phosphorylation. Peroxisome proliferator-
activated receptor γ coa tivator 1-alpha (PGC1α) plays an important role in regulating the oxidative
metabolism. When overexpressing PGC1α in mdx mice, increased mitochondrial biomass is noticed
along with improved Ca2+ handling in mitochondria in mdx muscle. Therefore, the nuclear receptors
peroxisome proliferator-activated receptor α and γ (PPARα and –γ) could be exploited as therapeutic
targets in DMD (Table 8) [144]. During inflammation, GCs collaborate with PPARα and -γ to diminish
chemokines [9]. The activation of PPARβ/δ in mdx mice by the PPARβ/δ agonist GW501516 stimulates
utrophin A expression and restores sarcolemmal integrity [144,145]. Another nuclear receptor,
Int. J. Mol. Sci. 2020, 21, 4596 14 of 25
mineralocorticoid receptor (MR), involved in skeletal muscle tissue protection, can promote NF-κB
during inflammation, which is counteracted by GCs binding to MRs. The MR-binding vamorolone was
shown to improve muscle function in DMD with fewer side-effects [11,146]. It increased membrane
stability, grip strength, and force, and also decreased inflammation, in mdx muscle [11]. Two Phase II
trials (NCT02760264 and NCT02760277) were conducted worldwide and completed in 2018, showing
good tolerance and improved muscle function in DMD boys [147]. Two Phase II trials (NCT03038399
and NCT03439670) are ongoing worldwide and should have been completed, respectively, in April
and May 2020.
Table 8. Overview of nuclear receptor stabilizing molecules: results in mdx myotubes (in vitro) or mice
(in vivo), finished clinical trials and results, ongoing clinical trials and due dates, and putative molecules.
Molecule Involved Pathway Results in mdxMyotubes or Mice
Finished Clinical Trials +
Results
Ongoing Clinical
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In Tables 1–8, summaries are provided, along with the outcomes, of finalized clinical trials using
stabilizing agents in DMD patients, as well as ongoing trials with their expected due dates [147].
Besides, results obtained with these agents in mdx mice are included. For all studies conducted on mdx
mice, one should keep in mind that these mice express a milder phenotype than that of DMD patients,
and extrapolation to the human condition should be done with care. The reasons for this phenomenon
reside in the ability of mdx mice to produce utrophin along with the presence of a high regenerative
capacity in their satellite cells [148].
When considering a polypharmaceutical approach for DMD patients, it is of the utmost importance
to know which molecules should never be combined with GCs. Cytochrome P450 3A4 (CYP3A4)
inhibitors, such as cobicistat (Gilead Sciences, Foster City, CA, USA), should not be administered
alongside GCs [149]. The combination of GCs with glucose lowering drugs, such as metformin,
requires great caution. It should be kept in mind that myostatin seems to be associated with the
GCs induced catabolic effect on muscle proteins [97] and HDACis can cause severe side-effects,
especially when combined with VPA [143]. In the past, a high dosage regimen of halofuginone, an
anti-parasitic molecule used in veterinary medicine, combined with GCs led to the death of a DMD
patient and abrogation of the clinical trial in 2016 [77]. One possible explanation could be found in the
synergy between halofuginone and GCs [90–93]. When considering polypharmacy in DMD, exploring
molecular interactions is of great importance in avoiding life-threatening drug combinations.
From the therapeutic armamentarium tested in mdx mice and in DMD patients, the vast majority
are molecules which were primarily designed for other diseases such as RA, Alzheimer’s disease,
and regulation of the blood pressure or glucose homeostasis, to name a few. When blocking an
entire pathway, such as the TGF-β, TLR, JAK/STAT or the glucose metabolism pathway, many other
functions in the cell will be affected with repercussions in the cellular activity, which can be noticed as
side-effects in patients (Tables 1–8). Inhibition of the TGF-β pathway seems to often produce side-effects
(Table 5) [85,92–95]. Although some molecules have not yet been tested in clinical trials with DMD
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patients, such as losartan, suramin, and decorin, the potential side-effects make these molecules less
attractive. The TGF-β cellular pathway is involved in many cellular functions ranging from cell growth
to apoptosis and should be considered as a cellular ‘highway’ which upon blocking is likely to yield
side-effects. Therefore, anti-TGF-β signaling drugs are challenging in finding a therapeutic window
and dosing regimen still efficacious and with only minor side effects [150]. Follistatin is an autocrine
glycoprotein expressed on nearly all cells of the body and side-effects were noticed during the Phase
I/II trial (NCT02354781). Inhibition of myostatin, a myokine, is muscle specific. Usage of antibodies
against myostatin will reveal in the near future their therapeutic value. The first outcome of the Phase
II (NCT02606136) clinical trial currently ongoing in the USA, should be known after completion of the
trial in April 2021.
Although the TLR-pathway is more oriented on the inflammatory response in skeletal muscle [151],
many downstream proteins have broad cellular function, especially MAPK, which plays an important
role in cellular proliferation [152]. From the TLR inhibitors listed as putative stabilizing agents,
NI-0101 was used in RA in a Phase II clinical trial and did not show any improvement in the disease
parameters [153]. Therefore, it may be less interesting to focus on this antibody. When considering
miRNAs as a therapeutic option in DMD, cautiousness is required as miRNAs can harbor several
modes of action. miR-146a deficiency in mdx mice did not aggravate the phenotype, but a slight increase
in muscle damage and inflammation was observed [154]. Therefore, inhibiting miR-146a should be
considered very carefully. Caution is also required when considering miR-21 inhibition. Indeed, in
mdx mice, miR-21 is increased in fibroblasts and downregulated in myoblasts [19], presumably making
it a difficult target. miR-206 is known for activating a large array of proteins such as HDAC4, PTB,
utrophin, Fstl1, Cx43, and TIMP3 and for inhibiting IGF-1, Pax3, and Pax7 [25]. Despite promising
results in mdx mice with (ALA)/L-carnitine (L-car) and its FDA approval, the absence of palmitoyl
carnitine hydrolase in DMD muscle and its essential role in carnitine metabolism, makes this molecule
uninteresting to consider as a stabilizing agent as it did not show any difference in function of
extremities in DMD patients [29–31]. Considering the JNK inhibitor JIP1 is less interesting as it is
generally administered through adenoviral infection, which makes it less suitable. The NF-κB inhibitors
PDTC and IRFI-042 and the AP-1 inhibitor batimastat (Table 3) can all be orally ingested. However,
batimastat displays a low oral bioavailability [155]. Neither PDTC nor IRFI-042 are FDA approved and
could therefore not be considered for clinical trials in conjunction with GCs [45–52,56]. The JAK/STAT
pathway stabilizing agent VPA, on the other hand, is FDA approved (ANDA 073229). It activates the
PI3K/Akt/mTOR pathway and reduces apoptosis. It may be worth considering for DMD clinical trials
yet keeping in mind it should never be combined with HDACis. This combination can trigger status
epilepticus [70,143]. Potential danger for DMD patients could also arise when combining glucose
lowering molecules with GCs, which should be avoided at any time (Table 6). Less dangerous, but
still detrimental, are the side-effects seen with HDACis (Table 7). With arrhythmias, nausea, vomiting,
anorexia, fatigue, anemia, and liver toxicities having been described, HDACis should be considered
very cautiously in DMD [143]. Therefore, it is understandable that the scientific community has high
hopes for vamorolone. Nevertheless, the cross-talk between the inflammatory and metabolic pathways
through p38 MAPK, mTOR, and Akt, as depicted in Figure 1, could lead to the combination of several
stabilizing molecules in conjunction with GCs and a subsequent decrease in GC-dosing. The theoretical
combination of GCs with VPA should first be tested in mdx mice. If beneficial effects are observed,
a polypharmaceutical approach could be applied in a clinical trial, potentially leading to smaller GC
regimens for DMD patients, which would be beneficial for their health.
Many research efforts are put in gene and cell therapies for DMD. To name some gene therapies:
exon skipping, stop codon readthrough, AAV-mediated therapies, RNA interference, clustered regularly
interspaced short palindromic repeats (CRISPR/Cas9), all with the intention to restore dystrophin
production in the DMD myocyte [156–160]. Cell therapies consist of autologous or allogenic muscle
stem cell implantation in DMD patients [161]. A mixed approach of gene therapy with cell therapy
along with GCs intake and supplementation of a steroid sparing agent such as VPA, could be worth
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considering. The cellular perturbations due to the lack of dystrophin and instable DAPC need to
be addressed along with restoring dystrophin expression by gene therapy. Polypharmacy in DMD
should always be applied after careful study of potentially life-threatening side-effects when combining
several molecules, to safeguard the life of our DMD patients.
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